文献速递神经肿瘤

双侧丘脑胶质瘤生存结局的预后因素:一项整合生存分析

Prognostic Factors for the Survival Outcome of Bilateral Thalamic Glioma: An Integrated Survival Analysis.
PubMed 文献 · World Neurosurg · 2017-11-02

该研究整合分析了双侧丘脑胶质瘤患者的生存数据,检索PubMed、Web of Science和Google Scholar中1964年至2017年5月发表的英文文献,并纳入本机构诊断的2例病例。共分析53例来自32篇已发表文章的病例及2例本机构病例。单因素分析显示症状持续时间、胶质瘤类型和世界卫生组织(WHO)分级与总生存期显著相关;多因素分析显示症状持续时间(HR 0.299,95%CI 0.121-0.736,P=0.009)和WHO分级(HR 4.639,95%CI 1.891-11.382,P=0.001)是双侧丘脑胶质瘤生存的独立预后因素。

要点

  • 较长症状持续时间(≥2个月)和低WHO分级与总生存期改善显著相关。
  • 症状持续时间和WHO分级是双侧丘脑胶质瘤总生存期的独立预后因素。
  • 单因素分析中胶质瘤类型与总生存期显著相关(log-rank P=0.001)。

核心结论

  • 较长的症状持续时间(≥2个月)和低WHO分级与改善的生存显著相关,且是总生存期的独立预后因素。

研究设计与样本

  • 对PubMed、Web of Science和Google Scholar中1964年至2017年5月发表的英文文献进行文献检索并提取生存分析所需信息,另纳入本机构诊断的2例病例。
  • 共纳入32篇已发表文章的53例病例及本机构的2例病例进行分析。

主要发现

  • 单因素分析显示症状持续时间(≥2个月或<2个月)、胶质瘤类型(星形细胞瘤或胶质母细胞瘤)和WHO分级(低级别或高级别)与总生存期显著相关,log-rank P分别为0.011、0.001和<0.001。
  • 多因素分析显示症状持续时间(HR 0.299,95%CI 0.121-0.736,P=0.009)和WHO分级(HR 4.639,95%CI 1.891-11.382,P=0.001)是双侧丘脑胶质瘤生存的独立预后因素。

关键数值与推荐

  • 症状持续时间与总生存期显著相关的log-rank P=0.011。
  • 胶质瘤类型与总生存期显著相关的log-rank P=0.001。
  • WHO分级与总生存期显著相关的log-rank P<0.001。
  • 症状持续时间的多因素分析HR 0.299(95%CI 0.121-0.736,P=0.009)。
  • WHO分级的多因素分析HR 4.639(95%CI 1.891-11.382,P=0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim of this study was to perform an integrated survival analysis of patients with bilateral thalamic glioma and to assess the influence of various prognostic factors on overall survival. METHODS: A literature search of PubMed, Web of Science, and Google Scholar was performed for literature in English published from 1964 to May 2017. Detailed information including demographics, clinical characteristics, treatments, critical events, and time to events for survival analysis were extracted from the included articles. In addition, 2 cases diagnosed in our institution were included. RESULTS: The study included 53 cases from 32 published articles and 2 cases from our institution that were selected for analysis. Univariate analysis showed the duration of symptoms (≥2 or <2 months), glioma type (astrocytoma or glioblastoma multiforme), and World Health Organization (WHO) grade (low or high) had a significant correlation with overall survival (log-rank P = 0.011, 0.001, and <0.001, respectively). Multivariate analysis showed that the duration of symptoms (hazard ratio [HR], 0.299; 95% confidence interval [CI], 0.121-0.736; P = 0.009), and WHO grade (HR, 4.639; 95% CI, 1.891-11.382; P = 0.001) were independent prognostic factors for bilateral thalamic glioma (BTG) survival. CONCLUSIONS: This comprehensive analysis of rare BTG patients revealed that a longer duration of symptoms (≥2 months) and low WHO grade were significantly associated with improved survival and were independent prognostic factors for overall survival.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Niu X, Wang T, Yang Y, et al. Prognostic Factors for the Survival Outcome of Bilateral Thalamic Glioma: An Integrated Survival Analysis. World Neurosurg. 2017. PMID: 29102752. doi:10.1016/j.wneu.2017.10.132

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。